Induction therapy with idarubicin alone significantly influences event-free survival duration in patients with newly diagnosed hypergranular acute promyelocytic leukemia: final results of the GIMEMA randomized study LAP 0389 with 7 years of minimal follow-up.
暂无分享,去创建一个
M. Baccarani | F. Mandelli | F. Lo‐Coco | G. Avvisati | F. Ferrara | N. Cantore | G. Mariani | S. Amadori | M. Lazzarino | G. Fioritoni | R. Invernizzi | C. Selleri | S. Sica | V. Liso | M. Petti | E. di Bona | F. Ricciuti | E. Gallo | D. Veneri | M. L. Vegna | Franco Mandelli | Simona Sica